Key Highlights
- CELC shares declined 0.49% to close at $65.25, followed by a 1.39% after-hours drop to $64.34.
- Median progression-free survival reached 21.5 months in patients without liver metastases receiving the triplet regimen.
- Overall response rate of 59% achieved in the triplet arm compared to 33% in the control cohort.
- Discontinuation due to adverse events was 5% for triplet and 4% for doublet, compared to 19% for alpelisib.
- Meta-analysis of eight clinical trials demonstrated progression-free survival advantages for gedatolisib-based therapies.
Celcuity unveiled encouraging clinical data from its VIKTORIA-1 Phase 3 study, demonstrating gedatolisib’s potential in treating advanced breast cancer. The latest analyses revealed extended disease control and improved patient responses across multiple subgroups. Despite these positive findings, CELC stock experienced downward pressure throughout both regular and extended trading sessions.
CELC Shares Retreat Following VIKTORIA-1 Data Presentation
Shares of Celcuity dropped 0.49% during the regular trading day, settling at $65.25—a decrease of $0.32. After-hours activity saw the stock slide an additional 1.39%, bringing the price down to $64.34. The decline occurred amid a session marked by price volatility despite the encouraging clinical trial updates.
Celcuity focuses on creating precision therapies for solid tumor malignancies, with gedatolisib representing a cornerstone of its oncology portfolio. Updated trial data were unveiled at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026. Dr. Barbara Pistilli from Gustave Roussy delivered the presentation detailing outcomes in the PIK3CA-mutant patient population.
The VIKTORIA-1 Phase 3 investigation evaluated gedatolisib-based regimens in individuals diagnosed with HR-positive, HER2-negative breast cancer that had progressed to an advanced stage. Investigators conducted head-to-head comparisons between gedatolisib combinations and standard therapies, notably the alpelisib-fulvestrant doublet. While the data bolster Celcuity’s pipeline strategy, these results alone do not guarantee regulatory clearance.
Extended Disease Control Observed in VIKTORIA-1 Subgroup Analysis
In patients who did not present with liver metastases, the gedatolisib-based triplet regimen yielded a median progression-free survival of 21.5 months. The control arm receiving alpelisib plus fulvestrant achieved a median of just 9.1 months. Statistical analysis showed a hazard ratio of 0.46, with p-value significance of 0.0016.
For those patients presenting with liver metastases, the triplet regimen produced a median progression-free survival of 9.1 months versus 4.6 months in the control cohort. The doublet configuration of gedatolisib reached 11.1 months in this particular subset. Each gedatolisib-containing regimen demonstrated statistically meaningful improvements over standard care in this group.
Additionally, patients without visceral disease involvement on the triplet therapy experienced 21.5 months of median progression-free survival compared to 9.2 months with conventional treatment. Those with visceral involvement recorded a median of 9.8 months on the triplet versus 5.6 months in the control group. The analyses revealed clinical benefits regardless of metastatic site, though patient numbers varied across subgroups.
Superior Response Metrics and Tolerability Profile Support Clinical Advancement
Within the PIK3CA-mutant population, the triplet configuration delivered an overall response rate of 59%, substantially exceeding the control arm’s 33% rate. The doublet formulation generated a 43% response rate, with triplet responses maintaining a median duration of 19.4 months. In contrast, the alpelisib-based control regimen showed a median response duration of merely 7.5 months.
The company also documented a 39% response rate for the triplet in patients harboring PIK3CA wild-type tumors. The doublet achieved 34%, whereas fulvestrant monotherapy managed only 1%. Furthermore, adverse events leading to treatment discontinuation occurred in just 5% of triplet recipients and 4% of doublet recipients.
Conversely, 19% of patients in the alpelisib arm discontinued therapy due to treatment-related side effects. An independent cross-trial evaluation spanning eight studies likewise demonstrated favorable progression-free survival outcomes for gedatolisib combinations when compared to alternative therapeutic approaches. Collectively, these metrics enhance Celcuity’s development trajectory, though cross-trial comparisons cannot substitute for randomized direct comparisons.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
